GordonMD Group Reports 3.83M Shares, 6.2% of PYXS in Schedule 13G

Rhea-AI Filing Summary

GordonMD entities and Craig D. Gordon report a passive 13G stake in Pyxis Oncology (PYXS). The filing shows that GordonMD Global Investments LP, GordonMD Long Biased Master Fund LP, GordonMD Long Biased GP LLC and Craig D. Gordon each report shared voting and dispositive power over 3,834,740 shares of Pyxis common stock, representing 6.2% of the class. All reported securities are owned by advisory clients of GordonMD Global Investments LP, with GordonMD Long Biased Master Fund LP identified as one advisory client that may hold more than 5%. The filing certifies the position is not intended to change or influence control of the issuer and includes a joint filing agreement and a control-person identification exhibit.

Positive

• Reported stake of 3,834,740 shares is clearly disclosed
• Represents 6.2% of the outstanding common stock, exceeding the 5% reporting threshold
• Filing classified as Schedule 13G, indicating the position is stated as passive (no intent to influence control)

Negative

• None.

Insights

Securities Analyst

TL;DR: A group of GordonMD entities and Craig D. Gordon report a passive 6.2% stake in PYXS.

The filing is a Schedule 13G, which indicates a non-control, passive investment position. It discloses 3,834,740 shares with shared voting and dispositive power across the reporting persons, equating to 6.2% of Pyxis Oncology's outstanding common stock. The report clarifies ownership arises from advisory clients of GordonMD Global Investments LP and identifies GordonMD Long Biased Master Fund LP as an advisory client that may exceed the 5% threshold. For investors, this documents a meaningful passive shareholding but contains no indication of activist intent or control transactions.

Corporate Governance Expert

TL;DR: The filing documents shared voting/dispositive power without sole control, consistent with passive investor disclosure.

The signatures and exhibits (Joint Filing Agreement and Control Person Identification) show coordination among affiliated entities and the individual reporting person. All reporting parties disclaim beneficial ownership beyond pecuniary interest and certify the position is not held to influence control. This aligns with the regulatory treatment of passive investors under Rule 13d-1(c) or (d). No governance changes, nominations, or control actions are disclosed.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Pyxis Oncology, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

747324101

(CUSIP Number)

07/14/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 747324101

1

Names of Reporting Persons

GordonMD Global Investments LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,834,740.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,834,740.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,834,740.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.2 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP No. 747324101

1

Names of Reporting Persons

GordonMD Long Biased Master Fund LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,834,740.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,834,740.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,834,740.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.2 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 747324101

1

Names of Reporting Persons

GordonMD Long Biased GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,834,740.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,834,740.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,834,740.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.2 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 747324101

1

Names of Reporting Persons

Craig D. Gordon

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,834,740.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,834,740.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,834,740.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.2 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Pyxis Oncology, Inc.
(b)	Address of issuer's principal executive offices: 321 HARRISON AVENUE, BOSTON, MA, 02118
Item 2.
(a)	Name of person filing: GordonMD Global Investments LP GordonMD Long Biased Master Fund LP GordonMD Long Biased GP LLC Craig D. Gordon
(b)	Address or principal business office or, if none, residence: GordonMD Global Investments LP 9460 WILSHIRE BLVD, SUITE 420, BEVERLY HILLS, CA, 90212 GordonMD Long Biased Master Fund LP 9460 WILSHIRE BLVD, SUITE 420, BEVERLY HILLS, CA, 90212 GordonMD Long Biased GP LLC 9460 WILSHIRE BLVD, SUITE 420, BEVERLY HILLS, CA, 90212 Craig D. Gordon 9460 WILSHIRE BLVD, SUITE 420, BEVERLY HILLS, CA, 90212
(c)	Citizenship: GordonMD Global Investments LP - Delaware GordonMD Long Biased Master Fund LP - Cayman Islands GordonMD Long Biased GP LLC - Delaware Craig D. Gordon - United States
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 747324101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: GordonMD Global Investments LP - 3,834,740 GordonMD Long Biased Master Fund LP - 3,834,740 GordonMD Long Biased GP LLC - 3,834,740 Craig D. Gordon - 3,834,740
(b)	Percent of class: GordonMD Global Investments LP - 6.2% GordonMD Long Biased Master Fund LP - 6.2% GordonMD Long Biased GP LLC - 6.2% Craig D. Gordon - 6.2%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: GordonMD Global Investments LP - 0 GordonMD Long Biased Master Fund LP - 0 GordonMD Long Biased GP LLC - 0 Craig D. Gordon - 0
	(ii) Shared power to vote or to direct the vote: GordonMD Global Investments LP - 3,834,740 GordonMD Long Biased Master Fund LP - 3,834,740 GordonMD Long Biased GP LLC - 3,834,740 Craig D. Gordon - 3,834,740
	(iii) Sole power to dispose or to direct the disposition of: GordonMD Global Investments LP - 0 GordonMD Long Biased Master Fund LP - 0 GordonMD Long Biased GP LLC - 0 Craig D. Gordon - 0
	(iv) Shared power to dispose or to direct the disposition of: GordonMD Global Investments LP - 3,834,740 GordonMD Long Biased Master Fund LP - 3,834,740 GordonMD Long Biased GP LLC - 3,834,740 Craig D. Gordon - 3,834,740
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. All of the securities reported in this Schedule 13G are directly owned by advisory clients of GordonMD Global Investments LP. None of those advisory clients, other than GordonMD Long Biased Master Fund LP may be deemed to beneficially own more than 5% of the Common Stock, $0.001 par value.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Please see Exhibit B attached hereto.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GordonMD Global Investments LP

Signature:	/s/ GordonMD Global Investments GP LLC
Name/Title:	Craig D. Gordon, Managing Member of the General Partner
Date:	09/23/2025

GordonMD Long Biased Master Fund LP

Signature:	/s/ GordonMD Long Biased GP LLC
Name/Title:	Craig D. Gordon, Managing Member of the General Partner
Date:	09/23/2025

GordonMD Long Biased GP LLC

Signature:	/s/ Craig D. Gordon
Name/Title:	Craig D. Gordon, Managing Member
Date:	09/23/2025

Craig D. Gordon

Signature:	/s/ Craig D. Gordon
Name/Title:	Craig D. Gordon
Date:	09/23/2025

Comments accompanying signature: * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.

Exhibit Information

Exhibit A - Joint Filing Agreement Exhibit B - Control Person Identification

FAQ

Who filed the Schedule 13G for Pyxis Oncology (PYXS)?

The filing was made by GordonMD Global Investments LP, GordonMD Long Biased Master Fund LP, GordonMD Long Biased GP LLC and Craig D. Gordon.

How many Pyxis Oncology shares are reported and what percent of the class is that?

The reporting persons disclose 3,834,740 shares, representing 6.2% of the class.

Does the Schedule 13G indicate these investors intend to influence control of PYXS?

No. The filing includes a certification that the securities were not acquired and are not held to change or influence control of the issuer.

What type of ownership powers are reported by the filers?

All reporting persons report 0 sole voting or dispositive power and 3,834,740 shared voting and dispositive power.

Are the reported shares owned directly by the filers or on behalf of others?

The filing states the securities are directly owned by advisory clients of GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP is identified as an advisory client that may beneficially own more than 5%.